WO2023277730A1 - Médicament pour la prévention d'une contamination par sars-cov-2 - Google Patents
Médicament pour la prévention d'une contamination par sars-cov-2 Download PDFInfo
- Publication number
- WO2023277730A1 WO2023277730A1 PCT/RU2022/000207 RU2022000207W WO2023277730A1 WO 2023277730 A1 WO2023277730 A1 WO 2023277730A1 RU 2022000207 W RU2022000207 W RU 2022000207W WO 2023277730 A1 WO2023277730 A1 WO 2023277730A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- sars
- cov
- rnase
- liposomes
- rna
- Prior art date
Links
- 239000003814 drug Substances 0.000 title claims abstract description 21
- 208000025721 COVID-19 Diseases 0.000 title claims abstract description 9
- 208000037847 SARS-CoV-2-infection Diseases 0.000 title claims abstract description 4
- 229940079593 drug Drugs 0.000 title claims description 16
- 238000011321 prophylaxis Methods 0.000 title abstract 3
- 239000002502 liposome Substances 0.000 claims abstract description 48
- 241001678559 COVID-19 virus Species 0.000 claims abstract description 41
- RJMUSRYZPJIFPJ-UHFFFAOYSA-N niclosamide Chemical compound OC1=CC=C(Cl)C=C1C(=O)NC1=CC=C([N+]([O-])=O)C=C1Cl RJMUSRYZPJIFPJ-UHFFFAOYSA-N 0.000 claims abstract description 29
- 229960001920 niclosamide Drugs 0.000 claims abstract description 29
- 238000011282 treatment Methods 0.000 claims abstract description 7
- 238000000034 method Methods 0.000 claims description 16
- 108020002230 Pancreatic Ribonuclease Proteins 0.000 claims description 8
- 102000005891 Pancreatic ribonuclease Human genes 0.000 claims description 8
- 208000001528 Coronaviridae Infections Diseases 0.000 claims description 7
- 230000002265 prevention Effects 0.000 claims description 7
- 229940126601 medicinal product Drugs 0.000 claims 1
- 102000006382 Ribonucleases Human genes 0.000 abstract description 46
- 108010083644 Ribonucleases Proteins 0.000 abstract description 46
- 108090000623 proteins and genes Proteins 0.000 abstract description 11
- 241000711573 Coronaviridae Species 0.000 abstract description 8
- 241000700605 Viruses Species 0.000 abstract description 8
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 abstract description 5
- 230000000840 anti-viral effect Effects 0.000 abstract description 5
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 5
- 208000025370 Middle East respiratory syndrome Diseases 0.000 abstract description 4
- 229940000425 combination drug Drugs 0.000 abstract description 4
- 239000002904 solvent Substances 0.000 abstract description 4
- 210000004779 membrane envelope Anatomy 0.000 abstract description 2
- 239000000126 substance Substances 0.000 abstract description 2
- 210000002845 virion Anatomy 0.000 abstract description 2
- 230000015556 catabolic process Effects 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 210000002345 respiratory system Anatomy 0.000 abstract 1
- 239000000203 mixture Substances 0.000 description 66
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 20
- 241001465754 Metazoa Species 0.000 description 15
- 241000283973 Oryctolagus cuniculus Species 0.000 description 15
- 239000000523 sample Substances 0.000 description 15
- 238000002474 experimental method Methods 0.000 description 12
- 108091034117 Oligonucleotide Proteins 0.000 description 10
- 230000009471 action Effects 0.000 description 10
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- 238000001502 gel electrophoresis Methods 0.000 description 8
- 238000001727 in vivo Methods 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 description 7
- 239000008347 soybean phospholipid Substances 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 241000283690 Bos taurus Species 0.000 description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 150000003904 phospholipids Chemical class 0.000 description 6
- 238000011534 incubation Methods 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 230000003612 virological effect Effects 0.000 description 5
- 238000010222 PCR analysis Methods 0.000 description 4
- 241000315672 SARS coronavirus Species 0.000 description 4
- 239000012620 biological material Substances 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 238000003776 cleavage reaction Methods 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 230000010076 replication Effects 0.000 description 4
- 238000003757 reverse transcription PCR Methods 0.000 description 4
- 230000007017 scission Effects 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 238000002123 RNA extraction Methods 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000001472 cytotoxic effect Effects 0.000 description 3
- 210000002950 fibroblast Anatomy 0.000 description 3
- 230000008014 freezing Effects 0.000 description 3
- 238000007710 freezing Methods 0.000 description 3
- 210000003494 hepatocyte Anatomy 0.000 description 3
- 229910001629 magnesium chloride Inorganic materials 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 238000010257 thawing Methods 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 239000011543 agarose gel Substances 0.000 description 2
- 210000002159 anterior chamber Anatomy 0.000 description 2
- 239000003443 antiviral agent Substances 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 2
- 229960004316 cisplatin Drugs 0.000 description 2
- 210000000795 conjunctiva Anatomy 0.000 description 2
- 210000004087 cornea Anatomy 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- JXTHNDFMNIQAHM-UHFFFAOYSA-N dichloroacetic acid Chemical compound OC(=O)C(Cl)Cl JXTHNDFMNIQAHM-UHFFFAOYSA-N 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000001917 fluorescence detection Methods 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 244000144993 groups of animals Species 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000002329 infrared spectrum Methods 0.000 description 2
- 210000000554 iris Anatomy 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 210000003928 nasal cavity Anatomy 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000011514 reflex Effects 0.000 description 2
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 2
- 210000003786 sclera Anatomy 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 108090001074 Nucleocapsid Proteins Proteins 0.000 description 1
- 238000009004 PCR Kit Methods 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 239000013614 RNA sample Substances 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 239000007984 Tris EDTA buffer Substances 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 230000001085 cytostatic effect Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 229960005215 dichloroacetic acid Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 210000001989 nasopharynx Anatomy 0.000 description 1
- 102000042567 non-coding RNA Human genes 0.000 description 1
- 108091027963 non-coding RNA Proteins 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 150000008300 phosphoramidites Chemical class 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 210000001747 pupil Anatomy 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 239000004055 small Interfering RNA Substances 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dispersion Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
Abstract
L'invention se rapporte au domaine de la médecine, de la pharmacie et des biotechnologies. L'invention concerne une nouvelle composition pharmaceutique ayant un effet antiviral en ce qui concerne le coronavirus SARS-CoV-2 et les virus apparentés comme le SARS, le MERS et autres, dont le génome est représenté par l'ARN tandis que les virions comportent une enveloppe lipidique. Ce médicament combiné pour la prophylaxie d'une contamination (pour le traitement de l'affection) par le SARS-CoV-2 comprend (i) un liposome avec une quantité efficace de ferment de RNAse, ou (ii) un liposome avec une quantité efficace de ferment de RNAse et une quantité efficace de préparation de niclosamide, et un excipient consistant en un solvant dont l'utilisation est autorisée en pharmacie. Cette invention permet de détruire le matériel génétique / ARN des coronavirus, ce qui permet d'effectuer un traitement contre des virus contenant de l'ARN, y compris le SARS-CoV-2, pénétrant dans l'organisme d'une personne via les voies respiratoires supérieures.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202280047238.2A CN117651550A (zh) | 2021-07-02 | 2022-06-30 | 用于预防SARS-CoV-2感染的药物 |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU2021119487 | 2021-07-02 | ||
| RU2021119487A RU2021119487A (ru) | 2021-07-02 | Комбинированное лекарственное средство, обладающее противовирусным эффектом для профилактики заражения SARS-CoV-2 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2023277730A1 true WO2023277730A1 (fr) | 2023-01-05 |
Family
ID=84690534
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/RU2022/000207 WO2023277730A1 (fr) | 2021-07-02 | 2022-06-30 | Médicament pour la prévention d'une contamination par sars-cov-2 |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN117651550A (fr) |
| WO (1) | WO2023277730A1 (fr) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090047272A1 (en) * | 2004-04-14 | 2009-02-19 | Appelbaum Jacob G | Compositions with Modified Nucleases Targeted to Viral Nucleic Acids and Methods of Use for Prevention and Treatment of Viral Diseases |
| US11045434B1 (en) * | 2020-04-01 | 2021-06-29 | UNION therapeutics A/S | Niclosamide formulations for treating disease |
-
2022
- 2022-06-30 CN CN202280047238.2A patent/CN117651550A/zh active Pending
- 2022-06-30 WO PCT/RU2022/000207 patent/WO2023277730A1/fr unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090047272A1 (en) * | 2004-04-14 | 2009-02-19 | Appelbaum Jacob G | Compositions with Modified Nucleases Targeted to Viral Nucleic Acids and Methods of Use for Prevention and Treatment of Viral Diseases |
| US11045434B1 (en) * | 2020-04-01 | 2021-06-29 | UNION therapeutics A/S | Niclosamide formulations for treating disease |
Non-Patent Citations (4)
| Title |
|---|
| CHRISTENSEN DENNIS ET AL.: "Cationic liposomes as vaccine adjuvants", EXPERT REVIEW OF VACCINES, vol. 6, no. 5, 2007, pages 785 - 796, XP008137314, DOI: 10.1586/14760584.6.5.785 * |
| ILYINSKAYA O.N., SHAH MAHMOOD R. : "Ribonukleazy kak protivovirusnye agenty", MOLEKULYARNAYA BIOLOGIYA, IZDATEL'STVO NAUKA, RU, vol. 48, no. 5, 30 November 2013 (2013-11-30), RU , pages 707 - 717, XP009542395, ISSN: 0026-8984, DOI: 10.7868/S0026898414040053 * |
| NISHIBATA YUKA, KOSHIMOTO SHOTA, OGAKI KENTA, ISHIKAWA ERIKA, WADA KOSUKE, YOSHINARI MIKU, TAMURA YUTO, UOZUMI RYO, MASUDA SAKIKO,: "RNase in the saliva can affect the detection of severe acute respiratory syndrome coronavirus 2 by real-time one-step polymerase chain reaction using saliva samples", PATHOLOGY - RESEARCH AND PRACTICE, ELSEVIER, AMSTERDAM, NL, vol. 220, 1 April 2021 (2021-04-01), AMSTERDAM, NL , pages 153381, XP093021765, ISSN: 0344-0338, DOI: 10.1016/j.prp.2021.153381 * |
| ROSSI GIOVANNI A. ET AL.: "Diferences and similarities between SARS-CoV and SARS-CoV-2: spike receptor-binding domain recognition and host cell infection with support of cellular serine proteases", INFECTION, vol. 48, 2020, pages 665 - 669, XP037255803, DOI: 10.1007/s15010-020-01486-5 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN117651550A (zh) | 2024-03-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20200339996A1 (en) | Anti-tnf compounds | |
| US10195145B2 (en) | Method for treating fibrosis using siRNA and a retinoid-lipid drug carrier | |
| US9629884B2 (en) | Compositions and methods for increasing lifespan and health span | |
| WO2005004903A1 (fr) | Methode de traitement de maladies oncologiques | |
| EP2349271A2 (fr) | Utilisation d inhibiteurs de récepteurs du type toll dans la prévention et le traitement de l hypercholestérolémie et de l hyperlipidémie et de maladies qui y sont associées | |
| CN101115505A (zh) | 治疗由过氧亚硝酸盐过度表达引起的哺乳动物疾病和创伤的方法和组合物 | |
| JP7001599B2 (ja) | 急性骨髄性白血病の処置のためのダクチノマイシン組成物および方法 | |
| KR20060063788A (ko) | 올리고 핵산 담지 복합체, 이 복합체를 함유하는 의약조성물 | |
| US20060241066A1 (en) | Decoy composition for treating and preventing inflammatory disease | |
| Xiaohong et al. | CFLAR is a critical regulator of cerebral ischaemia-reperfusion injury through regulating inflammation and endoplasmic reticulum (ER) stress | |
| JP2004512287A (ja) | 糖尿病性網膜症の予防または処置のための網膜細胞アポトーシス抑制剤の使用 | |
| CN110564842B (zh) | 细胞色素酶cyp26a1在制备治疗神经病理性疼痛的药物中的应用 | |
| EP1418922A1 (fr) | Compositions renfermant des phospholipides charges negativement et servant a traiter et/ou a prevenir la degenerescence maculaire et methode de fabrication associee | |
| WO2023277730A1 (fr) | Médicament pour la prévention d'une contamination par sars-cov-2 | |
| EA042253B1 (ru) | Комбинированное лекарственное средство, обладающее противовирусным эффектом для профилактики заражения sars-cov-2 | |
| EA043501B1 (ru) | ЛЕКАРСТВЕННОЕ СРЕДСТВО, ОБЛАДАЮЩЕЕ ПРОТИВОВИРУСНЫМ ЭФФЕКТОМ ДЛЯ ПРОФИЛАКТИКИ ЗАРАЖЕНИЯ SARS-CoV-2 | |
| Pan et al. | Valproate reduces retinal ganglion cell apoptosis in rats after optic nerve crush | |
| Shukurova et al. | A study into the effectiveness of the application of saffron extract in ocular pathologies in experiment | |
| US20110046209A1 (en) | RNA-Induced Translational Silencing and Cellular Apoptosis | |
| Gakhramanov | Effect of natural antioxidants on antioxidant activity and lipid peroxidation in eye tissue of rabbits with chemical burns | |
| US20070219150A1 (en) | Nerve Cell Differentiation Inducer | |
| WO2018027149A1 (fr) | Procédés de traitement du syndrome d'alport | |
| CN112569338B (zh) | Tdfa在制备预防和/或治疗眼表炎症疾病的药物中的应用 | |
| RU2245137C1 (ru) | Фармацевтическая композиция для лечения воспалительных процессов вирусной этиологии в глазном яблоке | |
| CN112972453B (zh) | MDL-800在制备抑制SARS-CoV-2病毒易感性药物中的应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22833748 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |